Trial tests prevention drugs in people at genetic risk for Alzheimer’s

The two biggest risk factors for late-onset Alzheimer's disease—age and carrying a risk gene—can't be changed. But what if people could do something to counteract those risks and possibly tip the balance in their favor? A groundbreaking clinical trial aims to find out if two experimental drugs can prevent or delay dementia in people at high genetic risk for developing the disorder.   The Alzheimer's Prevention Initiative's (API) Generation Study is seeking cognitively normal older adults with two copies of the APOE ɛ4 gene. People with two copies of this risk-factor gene are more likely than not to develop late-onset Alzheimer's, the most common form of the brain disorder, which so far has no cure.   Read the full article to learn more about the Generation Study and how to volunteer.   STAY CONNECTED          SUBSCRIBER SERVICES Manage Subscriptions | Subscription Help | Contact Us This email was sent to rssproject471@gmail.com using GovDelivery, on behalf of: National Institute on Aging · 31 Center Drive, MSC 2292 · Bethesda, MD · 20892 · 800-222-2225

Tweet

Postingan terkait:

— Tuesday, August 23, 2016 — Add Comment